AQST Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
7.6M
-45.3%
13.8M
-4.3%
14.4M
+11.0%
13.0M
+1.6%
12.8M
Cost of Revenue
3.6M
-10.2%
4.0M
+15.8%
3.5M
-40.6%
5.8M
+29.5%
4.5M
Gross Profit
4.0M
-59.7%
9.8M
-10.7%
11.0M
+52.9%
7.2M
-13.5%
8.3M
Operating Expenses
18.4M
+2.2%
18.0M
+18.7%
15.2M
-59.5%
37.5M
+89.3%
19.8M
R&D
4.3M
+7.3%
4.0M
-5.8%
4.2M
+31.5%
3.2M
-29.4%
4.5M
SG&A
14.2M
+0.8%
14.1M
+28.1%
11.0M
-66.6%
32.8M
+115.2%
15.3M
Operating Income
-14469000
-76.0%
-8223000
-95.6%
-4204000
+86.1%
-30272000
-163.7%
-11479000
EBITDA
-14313000
-77.0%
-8087000
-97.7%
-4091000
+86.4%
-30142000
-165.8%
-11340000
Net Income
-16496000
+27.9%
-22864000
-183.8%
-8057000
+74.7%
-31860000
-106.3%
-15446000
EPS (Basic)
$-0.13
+27.8%
$-0.18
-157.1%
$-0.07
+73.1%
$-0.26
-85.7%
$-0.14
EPS (Diluted)
$-0.13
+27.8%
$-0.18
-157.1%
$-0.07
+73.1%
$-0.26
-85.7%
$-0.14
Shares (Diluted)
125.5M
+0.4%
125.0M
+1.9%
122.6M
+0.3%
122.3M
+10.6%
110.6M
Aquestive Therapeutics (AQST) — Financials